---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Specific populations questions"
description: "Specific populations questions on Enhertu (fam-trastuzumab deruxtecan-nxki) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: Can Enhertu be used during pregnancy? How long is contraception needed after Enhertu? Can patients breastfeed while on Enhertu? Does Enhertu need a dose adjustment for kidney problems? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/enhertu/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Specific populations questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)  
Indication pages: [HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)

## Pregnancy and breastfeeding

<a id="enhertu-pregnancy"></a>

### Can Enhertu be used during pregnancy?

> “Embryo-Fetal Toxicity
>
> ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose of ENHERTU.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=3%20or%204.-,Embryo%2DFetal%20Toxicity,4%20months%20after%20the%20last%20dose%20of%20ENHERTU.)

> “Pregnancy: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months after the last dose of ENHERTU.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Pregnancy%3A%20ENHERTU%20can%20cause%20fetal,the%20last%20dose%20of%20ENHERTU.)

> “Monitor women who received ENHERTU during pregnancy or within 7 months 
> prior to conception for oligohydramnios. If oligohydramnios occurs, perform 
> fetal testing that is appropriate for gestational age and consistent with community 
> standards of care.”

Source: [ENHERTU: Prescribing information, page 16, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=16)

<a id="enhertu-contraception"></a>

### How long is contraception needed after Enhertu?

> “Females and Males of Reproductive Potential: Pregnancy testing: Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Contraception: Females: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for 7 months after the last dose. Males: Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Females%20and%20Males%20of%20Reproductive,male%20reproductive%20function%20and%20fertility.)

<a id="enhertu-breastfeeding"></a>

### Can patients breastfeed while on Enhertu?

> “Lactation: There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Lactation%3A%20There%20are%20no%20data,months%20after%20the%20last%20dose.)

## Specific populations

<a id="enhertu-renal-impairment"></a>

### Does Enhertu need a dose adjustment for kidney problems?

> “No dose adjustment of ENHERTU is recommended in patients with mild (creatinine 
> clearance [CLcr] 60 to <90 mL/min) or moderate (CLcr 30 to <60 mL/min) renal 
> impairment [see Clinical Pharmacology (12.3)].”

Source: [ENHERTU: Prescribing information, page 16, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=16)

> “Renal Impairment: A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Monitor patients with moderate renal impairment more frequently. The recommended dosage of ENHERTU has not been established for patients with severe renal impairment (CLcr <30 mL/min).”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Renal%20Impairment%3A%20A%20higher%20incidence,renal%20impairment%20%28CLcr%20%3C30%20mL%2Fmin%29.)

<a id="enhertu-hepatic-impairment"></a>

### Does Enhertu need a dose adjustment for liver problems?

> “No dose adjustment of ENHERTU is recommended in patients with mild (total 
> bilirubin ≤ULN and any AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST) 
> or moderate (total bilirubin >1.5 to 3 times ULN and any AST) hepatic impairment. 
> In patients with moderate hepatic impairment, due to potentially increased exposure, 
> monitor for increased adverse reactions related to the topoisomerase inhibitor, 
> DXd [see Dosage and Administration (2.3)]. The recommended dosage of ENHERTU 
> has not been established for patients with severe hepatic impairment (total 
> bilirubin >3 times ULN and any AST) [see Clinical Pharmacology (12.3)].”

Source: [ENHERTU: Prescribing information, page 17, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=17)

<a id="enhertu-older-adults"></a>

### Does Enhertu cause more side effects in older adults?

> “Geriatric Use: Of the 2233 patients treated with ENHERTU 5.4 mg/kg, 28% were ≥65 years and 6% were ≥75 years. No overall differences in efficacy within clinical studies were observed between patients ≥65 years compared to younger patients. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged ≥65 years (56%) as compared to younger patients (49%).”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Geriatric%20Use%3A%20Of%20the%202233,compared%20to%20younger%20patients%20%2849%25%29.)

Note: The 2233 patients are the pooled safety population across several tumor types treated with 5.4 mg/kg.

## Pediatric use

<a id="enhertu-pediatric-use"></a>

### Can Enhertu be used in children?

> “Pediatric Use: Safety and effectiveness of ENHERTU have not been established in pediatric patients.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Pediatric%20Use%3A%20Safety%20and%20effectiveness,been%20established%20in%20pediatric%20patients.)

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): All indications](https://www.evicenter.com/medical-information/enhertu)
- [Indication](https://www.evicenter.com/medical-information/enhertu/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/enhertu/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/enhertu/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/enhertu/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/enhertu/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/enhertu/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu/guidelines)
